Polo-like kinase 1 (PLK1) induces Vemurafenib resistance in melanoma.

Polo-like kinase 1 (PLK1) induces Vemurafenib resistance in melanoma.

<p><b>(A)</b> Relative cell viability under the treatment of Vemurafenib in mouse melanoma cells (mMC) and mouse melanoma with Plk1 knock-in (mMPI) cells. <i>n</i> = 3 biological replicates. Mean ± SD. n.s., <i>P</i> > 0.05; * <i>P</i> < 0....

Saved in:

书目详细资料
主要作者:	Fengyi Mao (15073242) (author)
其他作者:	Sai Wu (6096290) (author), Derek B. Allison (15141675) (author), Daheng He (9189701) (author), Yifan Kong (4458616) (author), Chaohao Li (15141681) (author), Zhiguo Li (431917) (author), Yanquan Zhang (14930570) (author), Xinyi Wang (559030) (author), Qiongsi Zhang (2818111) (author), Chi Wang (131921) (author), Xiaoqi Liu (45630) (author)
出版:	2025
主题:	Cell Biology Genetics Molecular Biology Developmental Biology Cancer Hematology Biological Sciences not elsewhere classified suppress tumor growth like kinase 1 crucial transcription factor cnc homolog 1 clinical database analysis shortened mice survival >< sup >< div >< p cutaneous melanoma based v600e </ sup patient survival pten </ ca </ ></ sup synergistic efficiency novel function negatively correlates genes involved cell cycle cancer progression cancer metabolism bach1 ), >- deficiency
标签:	添加标签没有标签, 成为第一个标记此记录!

Cannot write session to /tmp/vufind_sessions/sess_07j610p2kjp9lg0f82vlqkkg01